Cancer News and Research

Latest Cancer News and Research

New rates and benefits for 2011 from APWU Health Plan

APWU Health Plan announces new rates and benefits for 2011. APWU Health Plan continues to offer comprehensive health care to America's Workforce at a competitive premium. The average rate increase for the FEHB Program in 2011 is 7.2 percent. For the tenth straight year, the APWU Health Plan's rate increase was below the FEHB average.

15 Oct 2010

Aetna adds The Washington Hospital to provider network

Aetna announced that it has reached agreement with The Washington Hospital on a contract that adds a new hospital and potentially as many as 200 new physicians to Aetna's provider network in western Pennsylvania.

15 Oct 2010

EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma

Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.

15 Oct 2010

Access receives first MuGard prescriptions and reimbursement

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.

15 Oct 2010

Pericytes regulate blood-brain barrier

While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.

15 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

NASA software could help interpret medical imagery

NASA software used to enhance Earth science imagery could help interpret medical imagery. The new MED-SEG system, developed by Bartron Medical Imaging Inc. of Largo, Md., relies on an innovative software program developed at NASA to help doctors analyze mammograms, ultrasounds, digital X-rays and other medical imaging tests.

15 Oct 2010

EntreMed receives letter from NASDAQ Stock Market

EntreMed, Inc. a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced that it has received a letter from the NASDAQ Stock Market indicating that it has regained compliance with the minimum $35 million Market Value of Listed Securities requirement for continued listing on the NASDAQ Capital Market as set forth in NASDAQ Marketplace Rule 5550(b)(2).

15 Oct 2010

New development of genetic tool to speed discovery of novel genes involved in cancer

Researchers have developed a genetic tool in mice to speed the discovery of novel genes involved in cancer. The system - called PiggyBac - has already been used by the team to identify novel candidate cancer-causing genes.

15 Oct 2010

First Edition: October 15, 2010

Today's top stories from major news organizations report on the effort by 20 states to challenge the federal health law, a new federal panel to inform consumers about health care options and the struggle to pay for cancer care.

15 Oct 2010

A new therapeutic approach for cancer

Trials are being organized for a new therapeutic approach to treating cancer, under exclusive license by Viral Genetics, Inc. According to Scott & White Healthcare Senior Vice President for Research Richard E. Beswick, M.D., who is also assistant dean of research at the Texas A&M Health Science Center College of Medicine, the trials will be conducted at the Glenda Tanner Vasicek Cancer Treatment Center, located at Scott & White in Temple, Texas.

15 Oct 2010

Study highlights need to address overuse, underuse of colorectal cancer screening tests

Only one-fifth of primary care physicians in the US follow practice guidelines for colorectal cancer screening for all the tests they recommend, according to Dr. Robin Yabroff from the National Cancer Institute and her colleagues. About 40 percent followed guidelines for some of the tests they recommended and the remaining 40 percent did not follow guidelines for any of the screening tests they recommended.

15 Oct 2010

Research team creates first 'lipidome' of human plasma

Human blood is famously fraught with fats; now researchers have a specific idea of just how numerous and diverse these lipids actually are. A national research team, led by scientists at the University of California, San Diego School of Medicine, has created the first "lipidome" of human plasma, identifying and quantifying almost 600 distinct fat species circulating in human blood.

15 Oct 2010

MedSolutions, Corporate Research Group announce initial results from diagnostic accuracy program

MedSolutions and Corporate Research Group today announced initial results from a groundbreaking diagnostic accuracy program, which showed shortened hospital stays, reduced emergency room visits and lower overall medical costs among participants.

15 Oct 2010

Journal of Clinical Oncology publishes IPI-504 Phase 2 study results

Infinity Pharmaceuticals, Inc. announced that results from its Phase 2 study of IPI-504, a novel IV-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology.

15 Oct 2010

DFG to establish new Research Units

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing four new Research Units to facilitate cross-regional, interdisciplinary cooperation among researchers. This decision was taken by the DFG Senate at its autumn meeting in Bonn. The new groups are intended to enable researchers to devote themselves to current and urgent issues within their fields and to develop new approaches.

15 Oct 2010

Experts use multi-disciplinary approach to provide innovative care for children

Liver tumors affect more than 300 children in the United States each year and management of these children requires coordinated comprehensive care from experts in many disciplines. To answer this problem, Texas Children's Hospital and Baylor College of Medicine announced today the formation of a new Liver Tumor Center that brings together renowned specialists in all aspects of liver cancer who will utilize a multi-disciplinary approach to provide the most comprehensive and innovative care for children afflicted with these diseases.

15 Oct 2010

Caris Life Sciences presents new diagnostic data at ACG 2010

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic technologies, today announced upcoming highlights from the Company's presentations at the 2010 Annual Meeting of the American College of Gastroenterology ("ACG 2010") held in San Antonio, TX, October 15-20. In total, Caris was awarded 17 accepted abstracts, three of which are ACG Presidential Poster Award recipients.

15 Oct 2010

MRI-guided laser ablation offers way to kill tumors

Physicians at Mayo Clinic's Florida campus are among the first in the nation to use a technique known as MRI-guided laser ablation to heat up and destroy kidney and liver tumors. So far, five patients have been successfully treated meaning no visible tumors remained after the procedure.

15 Oct 2010

New insights into HIV infection process may allow antiviral drug development

New insights into the human immunodeficiency virus (HIV) infection process, which leads to acquired immunodeficiency syndrome (AIDS), may now be possible through a research method recently developed in part at the National Institute of Standards and Technology (NIST), where scientists have glimpsed an important protein molecule's behavior with unprecedented clarity.

15 Oct 2010